Market revenue in 2022 | USD 137.5 million |
Market revenue in 2030 | USD 211.7 million |
Growth rate | 5.5% (CAGR from 2022 to 2030) |
Largest segment | Estrogen and progesterone replacement therapy |
Fastest growing segment | Parathyroid Hormone replacement |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Estrogen and Progesterone Replacement Therapy, HGH replacement therapy, Thryoid hormone replacement therapy, Testosterone Replacement Therapy, Parathyroid Hormone replacement |
Key market players worldwide | Eli Lilly and Co, Bayer AG, Hisamitsu Pharmaceutical Co Inc, Pfizer Inc, Merck & Co Inc, Viatris Inc, Novo Nordisk A/S ADR, AbbVie Inc, Roche Holding AG ADR, Ascend Wellness Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hormone replacement therapy market will help companies and investors design strategic landscapes.
Estrogen and progesterone replacement therapy was the largest segment with a revenue share of 57.82% in 2022. Horizon Databook has segmented the Saudi Arabia hormone replacement therapy market based on estrogen and progesterone replacement therapy, hgh replacement therapy, thryoid hormone replacement therapy, testosterone replacement therapy, parathyroid hormone replacement covering the revenue growth of each sub-segment from 2018 to 2030.
The Saudi Arabia hormone replacement therapy market is anticipated to witness significant growth over the forecast period owing to strong healthcare infrastructure, easy access to treatment, and increasing prevalence of diseases. Furthermore, patent expiration o f key existing testosterone replacement therapy products is expected to drive market growth.
For instance, Endo Pharmaceuticals, Inc. is expected to lose its patent rights for Aveed 250MG/ML injection in March 2023 i n Saudi Arabia. Aveed is commonly used as testosterone replacement therapy to treat patients with male hypogonadism. I t costs around USD 800.4 0 per vial per patient. This patent expiration is expected to create new opportunities for big pharmaceutical companies in the market.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia hormone replacement therapy market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia hormone replacement therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account